2/3
11:33 am
legn
Legend Biotech (LEGN) Valuation Check After Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Legend Biotech (LEGN) Valuation Check After Recent Share Price Pullback [Yahoo! Finance]
2/2
09:44 am
legn
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss [Yahoo! Finance]
Low
Report
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss [Yahoo! Finance]
1/29
08:01 am
legn
GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco
Low
Report
GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco
1/26
03:29 am
legn
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline [Yahoo! Finance]
Low
Report
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline [Yahoo! Finance]
1/23
07:32 am
legn
Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds [Seeking Alpha]
Low
Report
Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds [Seeking Alpha]
1/22
08:06 am
legn
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
1/22
03:02 am
legn
Legend Biotech (NASDAQ:LEGN) was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..
Medium
Report
Legend Biotech (NASDAQ:LEGN) was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..
1/21
10:06 pm
legn
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
Medium
Report
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
1/21
08:00 am
legn
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
High
Report
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
1/20
03:13 pm
legn
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
1/20
12:47 pm
legn
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $66.00 price target on the stock.
Neutral
Report
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $66.00 price target on the stock.
1/20
06:59 am
legn
Legend Biotech (NASDAQ:LEGN) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Medium
Report
Legend Biotech (NASDAQ:LEGN) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
1/12
08:55 am
legn
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
08:00 am
legn
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
1/9
12:27 pm
legn
Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) [Yahoo! Finance]
Low
Report
Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) [Yahoo! Finance]
1/9
04:31 am
legn
Why The Legend Biotech LEGN Story Is Shifting As Carvykti And Competition Reframe Expectations [Yahoo! Finance]
Low
Report
Why The Legend Biotech LEGN Story Is Shifting As Carvykti And Competition Reframe Expectations [Yahoo! Finance]
1/7
09:00 am
legn
Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $75.00 price target on the stock.
Medium
Report
Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $75.00 price target on the stock.
1/6
08:00 am
legn
Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer
Low
Report
Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer
12/22
07:02 am
legn
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside [Yahoo! Finance]
Medium
Report
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside [Yahoo! Finance]
12/17
09:06 am
legn
Legend Biotech (NASDAQ:LEGN) was given a new $74.00 price target on by analysts at Cantor Fitzgerald.
Low
Report
Legend Biotech (NASDAQ:LEGN) was given a new $74.00 price target on by analysts at Cantor Fitzgerald.
12/17
08:43 am
legn
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
08:00 am
legn
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/12
12:00 pm
legn
Legend Biotech (NASDAQ:LEGN) was given a new $50.00 price target on by analysts at Morgan Stanley.
Low
Report
Legend Biotech (NASDAQ:LEGN) was given a new $50.00 price target on by analysts at Morgan Stanley.
12/11
05:31 pm
legn
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
Medium
Report
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
12/11
05:31 pm
legn
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
Medium
Report
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight